Indivior Pharmaceuticals, Inc. (INDV): Termination of a Material Definitive Agreement
Indivior Pharmaceuticals, Inc. (INDV) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. On September 9, 2026, Indivior UK Limited ("Indivior") and Reckitt Benckiser Healthcare (UK) Limited ("RB") entered into a Deed of Variation and Termination relating to that certain Copacker Supply Agreement dated December
How this was made
The 30-second read
Why it matters
The disclosed termination is described as non‑material, suggesting limited immediate trading relevance.
Market read
Primary disclosure of a contract termination with minimal material impact; low trading relevance.
What to watch
Potential supply chain disruptions or cost changes not disclosed in the filing.
Background
Indivior Pharmaceuticals, a specialty pharma company, disclosed termination of a long‑standing copacker agreement with Reckitt Benckiser.
Ticker impact
Indivior filed an 8‑K reporting the termination of its Copacker Supply Agreement with Reckitt Benckiser, accelerating the end date to Jan 15 2027.
minimal to none
The filing explicitly states costs are capped and not material, indicating limited market effect.
Market effects
Limited impact on the pharmaceutical manufacturing sector; similar contracts may be reviewed.
US and UK markets see no significant ripple.
Low
Counterpoint
If the new supplier faces delays, the termination could become material later.
Key entities
- companyIndivior Pharmaceuticals, Inc.
Issuer of the 8‑K filing.
- companyReckitt Benckiser Healthcare (UK) Limited
Former copacker for Suboxone® and Subutex® tablets.
